Back to search
Metastatic Mismatch Repair Proficient Colorectal Carcinoma
Clinical trial pipeline · Data from ClinicalTrials.gov
See which Metastatic Mismatch Repair Proficient Colorectal Carcinoma trials you may qualify forClinical trial pipeline · Data from ClinicalTrials.gov
See which Metastatic Mismatch Repair Proficient Colorectal Carcinoma trials you may qualify forThe main purpose of this study is to evaluate the safety and efficacy of novel study interventions and combinations in participants with Colorectal Cancer (CRC)…
This randomized, multi-site, three-part study will test a new treatment called BNT314, which is designed to help the body's immune system fight cancer in combin…
This is a prospective, randomized, open-label, multicenter phase II investigating the therapy of Fruquintinib in combination with Tislelizumab in patients with…
The goal of this clinical trial is to evaluate the safety and tolerability of escalating doses of ABT-301 in combination with fixed doses of tislelizumab 200 mg…
Single-arm, open-label, multicenter phase 2 clinical trial evaluating the clinical and the immunological activity of an innovative strategy with an induction co…
In this study, MMRd metastatic colorectal cancer (mCRC) patients who failed standard therapies will undergo treatment with pembrolizumab, while RAS-extended mut…
The main purpose of this study is to test the safety, tolerable side effects, and determine the highest tolerable dose of the combination of Regorafenib and Niv…